About Hydroxysteroid dehydrogenase-like protein 2
Hydroxysteroid dehydrogenase-like protein 2 (HSDL2) is a protein
from Homo sapiens identified by UniProt accession
Q6YN16, 418 residues long.
MolForge cross-references it against 0 known binders and
110 disease associations.
Target properties
| Protein name | Hydroxysteroid dehydrogenase-like protein 2 |
| UniProt accession | Q6YN16 |
| Gene | HSDL2 |
| Organism | Homo sapiens |
| Length | 418 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (110)
Diseases linked to this target (Open Targets).
- body height · score 0.34
- hip bone size · score 0.29
- hip bone mineral density · score 0.29
- chronotype measurement · score 0.25
- cholangiocarcinoma · score 0.10
- azoospermia · score 0.09
- papillary thyroid carcinoma · score 0.08
- calf circumference measurement · score 0.08
- melanoma · score 0.07
- pachyonychia congenita · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6YN16-F1 | alphafold | PREDICTED | 90.10 | — |
Amino-acid sequence (418 residues)
MLPNTGRLAG CTVFITGASR GIGKAIALKA AKDGANIVIA AKTAQPHPKL LGTIYTAAEE IEAVGGKALP CIVDVRDEQQ ISAAVEKAIK KFGGIDILVN NASAISLTNT LDTPTKRLDL MMNVNTRGTY LASKACIPYL KKSKVAHILN ISPPLNLNPV WFKQHCAYTI AKYGMSMYVL GMAEEFKGEI AVNALWPKTA IHTAAMDMLG GPGIESQCRK VDIIADAAYS IFQKPKSFTG NFVIDENILK EEGIENFDVY AIKPGHPLQP DFFLDEYPEA VSKKVESTGA VPEFKEEKLQ LQPKPRSGAV EETFRIVKDS LSDDVVKATQ AIYLFELSGE DGGTWFLDLK SKGGNVGYGE PSDQADVVMS MTTDDFVKMF SGKLKPTMAF MSGKLKIKGN MALAIKLEKL MNQMNARL
Explore Hydroxysteroid dehydrogenase-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets